Redeye comments on Annexin’s Q2 report and recent events in the company. Following the Q1 report, we implemented several updates to our model. With the Q2 figures now incorporated, only minor housekeeping adjustments have been made. The company is expected to initiate a phase IIa study in diabetes-induced retinopathy shortly, with potential for top-line data before year-end. Meanwhile, business development efforts continue.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/